Proliferation financing is the provision of funds or financial services used, in whole or in part, for the manufacture, acquisition, development, export, trans-shipment, brokering, transport or transfer of nuclear, chemical or biological weapons and their means of delivery, in breach of national or international obligations. It is inherently connected to the sanctions regimes administered by the Office of Financial Sanctions Implementation (OFSI), which target proliferators and the networks that fund them.
Inclusion in the UK framework
Until recently, proliferation financing was addressed in the UK mainly through sanctions. That changed with amendments to the Money Laundering Regulations 2017 that came into force in September 2022, requiring firms to identify and assess the risk of proliferation financing as part of their written risk assessment under Regulation 18A and to maintain proportionate policies, controls and procedures. The change aligned UK law with FATF Recommendation 1, which was updated to require an explicit proliferation-financing risk assessment.
Why it matters
Proliferation-financing schemes typically rely on deception: front companies, falsified documentation, dual-use goods and complex supply chains designed to evade sanctions screening. Detection therefore overlaps heavily with sanctions compliance and trade-finance controls. A firm that processes payments for a sanctioned proliferation network risks both sanctions breaches enforced by OFSI and broader AML failings under the MLRs 2017.
Who it applies to
All firms in the regulated sector under the MLRs 2017, with the heaviest practical burden on banks and institutions involved in trade finance, correspondent banking and cross-border payments.